Short Interest in Ipsen S.A. (OTCMKTS:IPSEY) Expands By 750.0%

Ipsen S.A. (OTCMKTS:IPSEY) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,700 shares, an increase of 750.0% from the November 15th total of 200 shares. Based on an average daily volume of 2,700 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada raised Ipsen from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 16th.

Ipsen Price Performance

IPSEY stock remained flat at $29.06 during mid-day trading on Thursday. The company’s stock had a trading volume of 205 shares, compared to its average volume of 1,438. Ipsen has a 12-month low of $27.00 and a 12-month high of $34.06. The stock’s 50 day moving average is $29.91 and its 200 day moving average is $30.23.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.